

Article number relates to Ethical Rules of the Pharmaceutical Industry (LER) (Chapter 2, section 3)

TEMPLATE												Date of publication:	31May2017	
	Full name  <i>(article 2)</i>	HCPs: City of Principal Practice HCOs: city of practice (registered address)  <i>(article 9)</i>	Country of principal practice  <i>(article 1)</i>	Principal practice address (e.g. clinic/office/healthcare unit/department)  <i>(article 9)</i>	Unique identifier - OPTIONAL  <i>(article 9)</i>	Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)			TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel and accomodation			
HCPs	<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate).</b>													
	Tero Hallikainen										4000 EUR		4000 EUR	
	<b>OTHER, not included above - where information cannot be disclosed on an individual basis with regard to the Swedish Data Protection Act (PUL) (1998:204)</b>													
	Aggregate amount attributable to transfers of value to such Recipients - article 10						N/A	N/A	Aggregate	Aggregate	Aggregate	Aggregate		
	Number of Recipients						N/A	N/A	number	number	number	number		
% of total number of recipients of individual HCPs						N/A	N/A	%	%	%	%		N/A	
HCOs	<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</b>													
								N/A	N/A					
								N/A	N/A					
								N/A	N/A					
								N/A	N/A					
<b>OTHER, not included above - where information cannot be disclosed per HCO for legal reasons</b>														
Aggregate amount attributable to transfers of value to such Recipients - article 10						Aggregate	Aggregate	N/A	N/A	Aggregate	Aggregate			
Number of Recipients						number	number	N/A	N/A	number	number			
% of total number of recipients of individual HCOs - article 10						%	%	N/A	N/A	%	%		N/A	
Not: N/A = Not Applicable														
R&D	<b>AGGREGATE DISCLOSURE</b>													
	Transfers of value re Research & Development (as defined) (article 12 and article 1)													